adalimumab vs SOR102
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Ulcerative Colitis
Shared mechanism: TNF-alpha · full Ulcerative Colitis pipeline
adalimumab · Humira
Marketed by AbbVie and partners
NCT00385736 · Phase 3 · completed
Design is strong (randomized, quadruple-blind, placebo-controlled, n=576, hard endoscopic/clinical Mayo remission endpoint), but the primary endpoint result was discordant across the two pre-specified dose-vs-placebo comparisons: one significant, one not. A well-designed trial with a mixed result is capped at moderate rather than strong.
Next expected readout: September 2027 · NCT06257875 (registry estimate)
Reported efficacy
Proportion of Participants Who Achieved Clinical Remission Per Mayo Score at Week 8; Proportion of Participants Who Achieved Clinical Remission Per Mayo Score at Week 52: Proportion of Participants Who Achieved Clinical Remission Per Mayo Score at Week 8 (Week 8): Adalimumab 160/80/40 16.5% vs Placebo 9.3%; p=0.019 (Adalimumab 160/80/40 vs Placebo) (met)
Result source: NCT00408629
SOR102
Developed by Sorriso Pharmaceuticals
NCT06080048 · Phase 1 · completed
Registry results were not posted at the time of grading; the key result shown was recovered from the cited external source. Its registered primary outcome on ClinicalTrials.gov is "Treatment Emergent Adverse Events following oral dosing". Its registered primary outcomes are safety, tolerability or dose-finding measures only, so the evidence grade is capped at weak.
Reported efficacy
Treatment Emergent Adverse Events following oral dosing (Up to 6 weeks in Part 3 or at the time of study discontinuation): First-in-human phase 1. Part 1 (healthy participants): treatment-emergent adverse events in 3/24 (13%) receiving SOR102 versus 2/8 (25%) receiving placebo. Part 2: no treatment-emergent adverse events in the 10 participants receiving twice-daily SOR102. Part 3 (ulcerative colitis patients): at least one adverse event in 7/16 (44%) treated with SOR102 and 3/6 (50%) receiving placebo. Rates of clinical response ranged from 29% to 67%, depending on the definition applied.
Result source: NCT06080048
Results for Ulcerative Colitis
Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.
| Key endpoint | adalimumab | SOR102 |
|---|---|---|
| Clinical remission (induction) | 10% vs 11.5%−1.5 vs placeboNCT008530996 other results
| —Not reported |
| Clinical remission (maintenance) | 20% vs 7.3%+12.7 vs placeboNCT0085309914 other results
| —Not reported |
| Clinical response (induction) | 50% vs 35.4%+14.6 vs placeboNCT008530994 other results
| —Not reported |
| Endoscopic improvement (induction) | 44.4% vs 30.2%+14.2 vs placeboNCT008530992 other results
| —Not reported |
| Corticosteroid-free remission (maintenance) | 13.3% vs 5.7%+7.6 vs placeboNCT004086295 other results
| —Not reported |
Clinical remission (induction)
- adalimumab
- 10% vs 11.5%−1.5 vs placeboNCT00853099
6 other results
- 13.8% vs 11.5% NCT00853099
- 10% vs 9.2% NCT00385736
- 18.5% vs 9.2% NCT00385736
- 16.5% vs 9.3% NCT00408629
- 10% vs 11.5% NCT00853099
- 13.8% vs 11.5% NCT00853099
- SOR102
- —Not reported
Clinical remission (maintenance)
- adalimumab
- 20% vs 7.3%+12.7 vs placeboNCT00853099
14 other results
- 26.4% vs 7.3% NCT00853099
- 17.3% vs 8.5% NCT00408629
- 29% vs 33.3% NCT02065557
- 45.2% vs 33.3% NCT02065557
- 27.3% vs 33.3% NCT02065557
- 42.9% vs 33.3% NCT02065557
- 20% vs 7.3% NCT00853099
- 17.8% vs 8.3% NCT00853099
- 26.4% vs 7.3% NCT00853099
- 17.2% vs 8.3% NCT00853099
- 42.9% vs 37.5% NCT02065557
- 45.5% vs 37.5% NCT02065557
- 42.9% vs 37.5% NCT02065557
- 44% vs 37.5% NCT02065557
- SOR102
- —Not reported
Clinical response (induction)
- adalimumab
- 50% vs 35.4%+14.6 vs placeboNCT00853099
4 other results
- 42.5% vs 35.4% NCT00853099
- 54.6% vs 44.6% NCT00385736
- 51.5% vs 44.6% NCT00385736
- 50.4% vs 34.6% NCT00408629
- SOR102
- —Not reported
Endoscopic improvement (induction)
- adalimumab
- 44.4% vs 30.2%+14.2 vs placeboNCT00853099
2 other results
- 39.1% vs 30.2% NCT00853099
- 41.1% vs 31.7% NCT00408629
- SOR102
- —Not reported
Corticosteroid-free remission (maintenance)
- adalimumab
- 13.3% vs 5.7%+7.6 vs placeboNCT00408629
5 other results
- 13.3% vs 5.7% NCT00408629
- 30.8% vs 40% NCT02065557
- 31.3% vs 40% NCT02065557
- 26.7% vs 40% NCT02065557
- 35.3% vs 40% NCT02065557
- SOR102
- —Not reported
- Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
- An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.
SOR102: no structured comparison results are available for Ulcerative Colitis.
Only safety results can currently be compared in this indication. Reviewed efficacy summaries, where available, are listed separately.
safety
Coverage. adalimumab: 4 of 4 rows · SOR102: 0 of 4 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.
| Reported metric | adalimumab |
|---|---|
| Dropout rate | 6.9%160/80/40a NCT00385736 · Phase 3 · monotherapy · Ulcerative Colitis · phase 3 show 18 more results9.2%80/40 NCT00385736 · Phase 3 · monotherapy · Ulcerative Colitis · phase 3 37.6%160/80/40 NCT00408629 · Phase 3 · Ulcerative Colitis · phase 3 —Adalimumab Group - Double-Blind Pe NCT00408629 · Phase 3 · monotherapy · Ulcerative Colitis · phase 3 52.5% NCT02632175 · Phase 3 · monotherapy —high dose NCT02065557 · Phase 3 · combination · Ulcerative Colitis · phase 3 —open-label high dose NCT02065557 · Phase 3 · combination · Ulcerative Colitis · phase 3 —standard dose NCT02065557 · Phase 3 · combination · Ulcerative Colitis · phase 3 —high dose NCT02065557 · Phase 3 · combination · Ulcerative Colitis · phase 3 —standard dose NCT02065557 · Phase 3 · combination · Ulcerative Colitis · phase 3 10.3%Induction (Main Study + Japan Sub- NCT02065622 · Phase 3 · combination · Ulcerative Colitis · phase 3 12.4%Induction (Main Study + Japan Sub- NCT02065622 · Phase 3 · combination · Ulcerative Colitis · phase 3 —Maintenance (Main Study + Japan Su NCT02065622 · Phase 3 · combination · Ulcerative Colitis · phase 3 —Maintenance (Main Study + Japan Su NCT02065622 · Phase 3 · combination · Ulcerative Colitis · phase 3 —Maintenance (Main Study): TDM Regi NCT02065622 · Phase 3 · monotherapy · Ulcerative Colitis · phase 3 56.4%40 mg EOW/EW NCT00573794 · Phase 3 · monotherapy 34.1%160 mg/80 mg NCT00853099 · Phase 3 · monotherapy · Ulcerative Colitis · phase 3 33.3%80 mg/40 mg NCT00853099 · Phase 3 · monotherapy · Ulcerative Colitis · phase 3 23.8% NCT01550965 · Phase 3 · monotherapy · Ulcerative Colitis · phase 3 |
| Discontinued due to AEs | 3.1%160/80/40a NCT00385736 · Phase 3 · monotherapy · Ulcerative Colitis · phase 3 show 18 more results4.6%80/40 NCT00385736 · Phase 3 · monotherapy · Ulcerative Colitis · phase 3 5%160/80/40 NCT00408629 · Phase 3 · Ulcerative Colitis · phase 3 —Adalimumab Group - Double-Blind Pe NCT00408629 · Phase 3 · monotherapy · Ulcerative Colitis · phase 3 — NCT02632175 · Phase 3 · monotherapy —high dose NCT02065557 · Phase 3 · combination · Ulcerative Colitis · phase 3 —open-label high dose NCT02065557 · Phase 3 · combination · Ulcerative Colitis · phase 3 —standard dose NCT02065557 · Phase 3 · combination · Ulcerative Colitis · phase 3 —high dose NCT02065557 · Phase 3 · combination · Ulcerative Colitis · phase 3 —standard dose NCT02065557 · Phase 3 · combination · Ulcerative Colitis · phase 3 3.3%Induction (Main Study + Japan Sub- NCT02065622 · Phase 3 · combination · Ulcerative Colitis · phase 3 3.4%Induction (Main Study + Japan Sub- NCT02065622 · Phase 3 · combination · Ulcerative Colitis · phase 3 —Maintenance (Main Study + Japan Su NCT02065622 · Phase 3 · combination · Ulcerative Colitis · phase 3 —Maintenance (Main Study + Japan Su NCT02065622 · Phase 3 · combination · Ulcerative Colitis · phase 3 —Maintenance (Main Study): TDM Regi NCT02065622 · Phase 3 · monotherapy · Ulcerative Colitis · phase 3 13.8%40 mg EOW/EW NCT00573794 · Phase 3 · monotherapy 14.3%160 mg/80 mg NCT00853099 · Phase 3 · monotherapy · Ulcerative Colitis · phase 3 10.3%80 mg/40 mg NCT00853099 · Phase 3 · monotherapy · Ulcerative Colitis · phase 3 5.6% NCT01550965 · Phase 3 · monotherapy · Ulcerative Colitis · phase 3 |
| Serious AEs | 4%160/80/40a NCT00385736 · Phase 3 · monotherapy · Ulcerative Colitis · phase 3 show 18 more results3.8%80/40 NCT00385736 · Phase 3 · monotherapy · Ulcerative Colitis · phase 3 —160/80/40 NCT00408629 · Phase 3 · Ulcerative Colitis · phase 3 12.1%Adalimumab Group - Double-Blind Pe NCT00408629 · Phase 3 · monotherapy · Ulcerative Colitis · phase 3 27.1% NCT02632175 · Phase 3 · monotherapy 7.8%high dose NCT02065557 · Phase 3 · combination · Ulcerative Colitis · phase 3 5.6%open-label high dose NCT02065557 · Phase 3 · combination · Ulcerative Colitis · phase 3 15.6%standard dose NCT02065557 · Phase 3 · combination · Ulcerative Colitis · phase 3 13.9%high dose NCT02065557 · Phase 3 · combination · Ulcerative Colitis · phase 3 15.2%standard dose NCT02065557 · Phase 3 · combination · Ulcerative Colitis · phase 3 3.8%Induction (Main Study + Japan Sub- NCT02065622 · Phase 3 · combination · Ulcerative Colitis · phase 3 5%Induction (Main Study + Japan Sub- NCT02065622 · Phase 3 · combination · Ulcerative Colitis · phase 3 12.6%Maintenance (Main Study + Japan Su NCT02065622 · Phase 3 · combination · Ulcerative Colitis · phase 3 12.8%Maintenance (Main Study + Japan Su NCT02065622 · Phase 3 · combination · Ulcerative Colitis · phase 3 9.9%Maintenance (Main Study): TDM Regi NCT02065622 · Phase 3 · monotherapy · Ulcerative Colitis · phase 3 26.7%40 mg EOW/EW NCT00573794 · Phase 3 · monotherapy 11.1%160 mg/80 mg NCT00853099 · Phase 3 · monotherapy · Ulcerative Colitis · phase 3 16.1%80 mg/40 mg NCT00853099 · Phase 3 · monotherapy · Ulcerative Colitis · phase 3 14.5% NCT01550965 · Phase 3 · monotherapy · Ulcerative Colitis · phase 3 |
| Most frequent reported AEs | 160/80/40a colitis ulcerative 4% (placebo 3.6%) fatigue 4% (placebo 2.2%) headache 3.1% (placebo 7.2%) NCT00385736 · Phase 3 · monotherapy · Ulcerative Colitis · phase 3 show 17 more results80/40 headache 6.9% (placebo 7.2%) colitis ulcerative 5.4% (placebo 3.6%) nasopharyngitis 4.6% (placebo 1.8%) NCT00385736 · Phase 3 · monotherapy · Ulcerative Colitis · phase 3 nasopharyngitis 17.5% (placebo 10.4%) colitis ulcerative 16.3% (placebo 22.3%) headache 8.6% (placebo 14.2%) NCT00408629 · Phase 3 · monotherapy · Ulcerative Colitis · phase 3 colitis ulcerative 33.9% upper respiratory tract infection 27.1% nasopharyngitis 22% NCT02632175 · Phase 3 · monotherapy high dose headache 9.8% (placebo 16.7%) anaemia 5.9% (placebo 8.3%) nausea 5.9% (placebo 0%) NCT02065557 · Phase 3 · combination · Ulcerative Colitis · phase 3 open-label high dose headache 22.2% (placebo 16.7%) abdominal pain 11.1% (placebo 8.3%) oropharyngeal pain 11.1% (placebo 0%) NCT02065557 · Phase 3 · combination · Ulcerative Colitis · phase 3 standard dose headache 12.5% (placebo 16.7%) colitis ulcerative 6.3% (placebo 16.7%) nasopharyngitis 6.3% (placebo 8.3%) NCT02065557 · Phase 3 · combination · Ulcerative Colitis · phase 3 high dose colitis ulcerative 11.1% (placebo 16.7%) nasopharyngitis 11.1% (placebo 8.3%) upper respiratory tract infection 11.1% (placebo 16.7%) NCT02065557 · Phase 3 · combination · Ulcerative Colitis · phase 3 standard dose headache 18.2% (placebo 16.7%) c-reactive protein increased 9.1% (placebo 0%) colitis ulcerative 9.1% (placebo 16.7%) NCT02065557 · Phase 3 · combination · Ulcerative Colitis · phase 3 headache 8.4% nasopharyngitis 5.1% arthralgia 3.1% NCT02065622 · Phase 3 · combination · Ulcerative Colitis · phase 3 headache 6.1% colitis ulcerative 5.3% nasopharyngitis 4.2% NCT02065622 · Phase 3 · combination · Ulcerative Colitis · phase 3 colitis ulcerative 13.4% nasopharyngitis 13.1% arthralgia 6.6% NCT02065622 · Phase 3 · combination · Ulcerative Colitis · phase 3 colitis ulcerative 17.4% nasopharyngitis 13.6% arthralgia 6.7% NCT02065622 · Phase 3 · combination · Ulcerative Colitis · phase 3 colitis ulcerative 15.2% nasopharyngitis 7.3% upper respiratory tract infection 6% NCT02065622 · Phase 3 · monotherapy · Ulcerative Colitis · phase 3 40 mg EOW/EW colitis ulcerative 30.4% viral upper respiratory tract infection 19.4% arthralgia 10.5% NCT00573794 · Phase 3 · monotherapy 160 mg/80 mg nasopharyngitis 33.3% (placebo 21.9%) iron deficiency anaemia 8.9% (placebo 7.3%) headache 7.8% (placebo 6.3%) NCT00853099 · Phase 3 · monotherapy · Ulcerative Colitis · phase 3 80 mg/40 mg nasopharyngitis 21.8% (placebo 21.9%) injection site reaction 8% (placebo 2.1%) dental caries 6.9% (placebo 5.2%) NCT00853099 · Phase 3 · monotherapy · Ulcerative Colitis · phase 3 colitis ulcerative 13.2% headache 13% nasopharyngitis 8% NCT01550965 · Phase 3 · monotherapy · Ulcerative Colitis · phase 3 |
Notes
- aPopulation comparability has not been reviewed for 2 of these studies.
Reported by one asset only
Endpoints only one of the selected assets measured, so there is nothing to compare them against.
adalimumab
show 6 more results
show 4 more results
show 1 more result
show 1 more result
show 1 more result
show 1 more result
show 4 more results
show 14 more results
show 8 more results
show 2 more results
+ 51 further endpoints in the CSV export.
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: adalimumab's landscape · SOR102's landscape